文献速递淋巴瘤

套细胞淋巴瘤免化疗策略的潜力

The potential for chemotherapy-free strategies in mantle cell lymphoma.
PubMed 文献 · Blood · 2017-09-12

套细胞淋巴瘤(MCL)是少数将多种化疗与非化疗方案均视为标准的癌症之一。高增殖及TP53突变患者对强化细胞毒治疗反应差,合并症多或地理隔离者可能无法获得最有前景的方案。非化疗药物可能克服TP53突变等不良预后因素,并解决标准化疗毒性与可及性挑战;多项试验显示非化疗联合化疗可影响结局,单用或联合非化疗药物提示部分患者可能适合完全免化疗。

要点

  • 高增殖或TP53突变的MCL患者对强化细胞毒治疗反应差。
  • 合并症多或地理隔离者可能无法获得临床试验中最有前景的方案。
  • 非化疗药物可能克服TP53突变等不良预后因素并改善可及性。

核心结论

  • 非化疗时代已到来,其发展取决于如何应对慢性或意外毒性、联合方案的理性与实用性开发及新策略的财务可接受性等挑战。

研究设计与样本

  • 综述,讨论MCL中化疗与非化疗方案的潜力与挑战。

主要发现

  • 高增殖MCL及TP53突变患者尽管接受强化细胞毒治疗仍反应差。
  • 合并症多及地理隔离患者可能无法获得临床试验中最有前景的方案。
  • 多项临床试验显示非化疗联合化疗药物可影响结局。
  • 单用或联合非化疗药物的数据提示部分患者可能适合完全免化疗。

关键数值与推荐

  • 非化疗药物可能克服TP53突变等不良预后因素,并可能解决标准化疗毒性与可及性挑战。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 慢性或意外毒性、联合方案的理性与实用性开发、新策略的财务可接受性等挑战广泛存在。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mantle cell lymphoma (MCL) may be 1 of the few cancers for which multiple chemotherapy and nonchemotherapy regimens are considered as standard. Despite the significant activity of chemotherapy in the first-line setting and beyond, its limitations are reflected in the relatively poor ultimate outcomes of patients with MCL treated in the real world. Patients with highly proliferative MCL and those with TP53 mutations tend to respond poorly despite intensive cytotoxic therapies. Patients with comorbidities and those who are geographically isolated may not have access to the regimens that may appear most promising in clinical trials. Thoughtfully directed, nonchemotherapy agents might overcome some of the factors associated with a poor prognosis, such at TP53 mutation, and might resolve some of the challenges related to the toxicity and deliverability of standard chemotherapy regimens. Several clinical trials have already demonstrated that combinations of nonchemotherapy plus chemotherapy drugs can impact outcomes, whereas data with nonchemotherapy agents alone or in combination have suggested that some patients might be well suited to treatment without chemotherapy at all. However, challenges including chronic or unexpected toxicities, the rational vs practical development of combinations, and the financial acceptability of new strategies abound. The nonchemotherapy era is here: how it unfolds will depend on how we meet these challenges.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Martin P, Ruan J, Leonard JP, et al. The potential for chemotherapy-free strategies in mantle cell lymphoma. Blood. 2017. PMID: 28899853. doi:10.1182/blood-2017-05-737510

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。